10-Q Filing

BEONE MEDICINES LTD. CIK: 1651308 Q2 2018

Filing Information

Form Type	10-Q
Accession Number	`0001558370-18-006821`
Period End Date	20180630
Filing Date	20180809
Fiscal Year	2018
Fiscal Period	Q2
XBRL Instance	bgne-20180630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 82 Income Statement 70 Cash Flow Statement 77 Comprehensive Income 24

Balance Sheet 82 line items

Line Item	Tag	Value	Unit	Period
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Ordinary shares, shares authorized	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$261.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$239.60M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$438.42M	USD	Point-in-time
Ordinary shares, shares authorized	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Restricted Cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$31.59M	USD	Point-in-time
Ordinary shares, shares issued	`CommonStockSharesIssued`	592.07M	shares	Point-in-time
Ordinary shares, shares issued	`CommonStockSharesIssued`	701.56M	shares	Point-in-time
Short-term investments	`ShortTermInvestments`	$597.91M	USD	Point-in-time
Ordinary shares, shares outstanding	`CommonStockSharesOutstanding`	701.56M	shares	Point-in-time
Short-term investments	`ShortTermInvestments`	$931.21M	USD	Point-in-time
Ordinary shares, shares outstanding	`CommonStockSharesOutstanding`	592.07M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$29.43M	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$33.17M	USD	Point-in-time
Unbilled receivable	`UnbilledReceivablesCurrent`	$12.70M	USD	Point-in-time
Unbilled receivable	`UnbilledReceivablesCurrent`	$16.31M	USD	Point-in-time
Inventories	`InventoryNet`	$10.93M	USD	Point-in-time
Inventories	`InventoryNet`	$6.32M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$63.29M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$35.62M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$913.50M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.52B	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$62.57M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$90.51M	USD	Point-in-time
Land use right, net	`LandUseRightNet`	$12.46M	USD	Point-in-time
Land use right, net	`LandUseRightNet`	$12.13M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$7.25M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$6.88M	USD	Point-in-time
Goodwill	`Goodwill`	$109.00K	USD	Point-in-time
Goodwill	`Goodwill`	$109.00K	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$7.67M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$16.07M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$42.91M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$11.45M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$137.15M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$132.98M	USD	Point-in-time
Total assets	`Assets`	$1.65B	USD	Point-in-time
Total assets	`Assets`	$1.05B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$85.88M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$69.78M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrent`	$75.04M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrent`	$49.60M	USD	Point-in-time
Deferred revenue, current portion	`ContractWithCustomerLiabilityCurrent`	$15.30M	USD	Point-in-time
Deferred revenue, current portion	`ContractWithCustomerLiabilityCurrent`	$12.23M	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$9.16M	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$1.15M	USD	Point-in-time
Current portion of long-term bank loan	`LongTermDebtCurrent`	$9.07M	USD	Point-in-time
Current portion of long-term bank loan	`LongTermDebtCurrent`	$9.22M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$149.99M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$186.44M	USD	Point-in-time
Long-term bank loan	`LongTermDebtNoncurrent`	$9.22M	USD	Point-in-time
Long-term bank loan	`LongTermDebtNoncurrent`	$51.47M	USD	Point-in-time
Shareholder loan	`DueToRelatedPartiesNoncurrent`	$149.22M	USD	Point-in-time
Shareholder loan	`DueToRelatedPartiesNoncurrent`	$146.27M	USD	Point-in-time
Deferred revenue, non-current portion	`ContractWithCustomerLiabilityNoncurrent`	$18.30M	USD	Point-in-time
Deferred revenue, non-current portion	`ContractWithCustomerLiabilityNoncurrent`	$24.81M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$31.96M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$21.77M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$212.26M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$240.75M	USD	Point-in-time
Total liabilities	`Liabilities`	$427.19M	USD	Point-in-time
Total liabilities	`Liabilities`	$362.25M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Ordinary shares (par value of US$0.0001 per share; 9,500,000,000 shares authorized; 701,563,184 shares issued and outstanding as of June 30, 2018 (December 31, 2017: 592,072,330 shares))	`CommonStockValue`	$59.00K	USD	Point-in-time
Ordinary shares (par value of US$0.0001 per share; 9,500,000,000 shares authorized; 701,563,184 shares issued and outstanding as of June 30, 2018 (December 31, 2017: 592,072,330 shares))	`CommonStockValue`	$70.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.00B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.80B	USD	Point-in-time
Accumulated other comprehensive income /(loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$3.11M	USD	Point-in-time
Accumulated other comprehensive income /(loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-480.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-594.93M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-330.52M	USD	Point-in-time
Total BeiGene, Ltd. Shareholders' equity	`StockholdersEquity`	$669.81M	USD	Point-in-time
Total BeiGene, Ltd. Shareholders' equity	`StockholdersEquity`	$1.21B	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$13.47M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$14.42M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.23B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$684.23M	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$1.05B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$1.65B	USD	Point-in-time

Income Statement 70 line items

Line Item	Tag	Value	Unit	Period
Revenues	`Revenues`	$85.35M	USD	2 Qtrs
Revenues	`Revenues`	$52.80M	USD	1 Quarter
Revenues	`Revenues`	-	USD	2 Qtrs
Revenues	`Revenues`	-	USD	1 Quarter
Cost of sales - product	`CostOfGoodsAndServicesSold`	$6.26M	USD	1 Quarter
Cost of sales - product	`CostOfGoodsAndServicesSold`	$10.81M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$90.02M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$164.25M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$47.24M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$273.95M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$74.08M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$19.55M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$45.16M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$10.78M	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$187.00K	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$375.00K	USD	2 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	-	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	-	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$359.21M	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$58.02M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$215.85M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$109.56M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-58.02M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-163.05M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-109.56M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-273.86M	USD	2 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNet`	$3.44M	USD	2 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNet`	$-1.98M	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNet`	$1.89M	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNet`	$-1.80M	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$804.00K	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-475.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$75.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$438.00K	USD	2 Qtrs
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-110.92M	USD	2 Qtrs
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-60.48M	USD	1 Quarter
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-161.08M	USD	1 Quarter
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-269.61M	USD	2 Qtrs
Income tax benefit (expense)	`IncomeTaxExpenseBenefit`	$201.00K	USD	1 Quarter
Income tax benefit (expense)	`IncomeTaxExpenseBenefit`	$-3.37M	USD	1 Quarter
Income tax benefit (expense)	`IncomeTaxExpenseBenefit`	$381.00K	USD	2 Qtrs
Income tax benefit (expense)	`IncomeTaxExpenseBenefit`	$-6.78M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-262.83M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-60.68M	USD	1 Quarter
Net loss	`ProfitLoss`	$-157.72M	USD	1 Quarter
Net loss	`ProfitLoss`	$-111.30M	USD	2 Qtrs
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.35M	USD	2 Qtrs
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-135.00K	USD	1 Quarter
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-828.00K	USD	1 Quarter
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-135.00K	USD	2 Qtrs
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-261.48M	USD	2 Qtrs
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-60.55M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-156.89M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-111.17M	USD	2 Qtrs
Basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.22	USD	2 Qtrs
Basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.22	USD	1 Quarter
Basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.38	USD	2 Qtrs
Basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.12	USD	1 Quarter
Basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	517.05M	shares	2 Qtrs
Basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	698.51M	shares	1 Quarter
Basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	517.66M	shares	1 Quarter
Basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	684.59M	shares	2 Qtrs
Basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-2.80	USD	2 Qtrs
Basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-4.97	USD	2 Qtrs
Basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-2.92	USD	1 Quarter
Basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-1.52	USD	1 Quarter
Basic and diluted (in ADSs) (in shares)	`WeightedAverageNumberOfAmericanDepositarySharesOutstandingBasicAndDiluted`	39.77M	shares	2 Qtrs
Basic and diluted (in ADSs) (in shares)	`WeightedAverageNumberOfAmericanDepositarySharesOutstandingBasicAndDiluted`	53.73M	shares	1 Quarter
Basic and diluted (in ADSs) (in shares)	`WeightedAverageNumberOfAmericanDepositarySharesOutstandingBasicAndDiluted`	39.82M	shares	1 Quarter
Basic and diluted (in ADSs) (in shares)	`WeightedAverageNumberOfAmericanDepositarySharesOutstandingBasicAndDiluted`	52.66M	shares	2 Qtrs

Cash Flow Statement 77 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-262.83M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-60.68M	USD	1 Quarter
Net loss	`ProfitLoss`	$-157.72M	USD	1 Quarter
Net loss	`ProfitLoss`	$-111.30M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$1.40M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$4.58M	USD	2 Qtrs
Share-based compensation expenses	`ShareBasedCompensation`	$13.07M	USD	2 Qtrs
Share-based compensation expenses	`ShareBasedCompensation`	$36.04M	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$10.00M	USD	2 Qtrs
Non-cash interest expense	`InterestExpenseOperatingActivities`	$2.23M	USD	2 Qtrs
Non-cash interest expense	`InterestExpenseOperatingActivities`	$4.12M	USD	2 Qtrs
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-8.41M	USD	2 Qtrs
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-4.06M	USD	2 Qtrs
Other non-cash income	`OtherNoncashIncomeExpense`	$3.00K	USD	2 Qtrs
Other non-cash income	`OtherNoncashIncomeExpense`	$2.34M	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$3.74M	USD	2 Qtrs
Unbilled receivable	`IncreaseDecreaseInUnbilledReceivables`	$-3.60M	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$-4.61M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$5.04M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$27.67M	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$139.00K	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$3.69M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$10.31M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$13.24M	USD	2 Qtrs
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$130.00K	USD	2 Qtrs
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$25.44M	USD	2 Qtrs
Tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$2.30M	USD	2 Qtrs
Tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$-8.01M	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-3.44M	USD	2 Qtrs
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$-197.00K	USD	2 Qtrs
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$559.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-87.60M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-221.64M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$8.88M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$20.31M	USD	2 Qtrs
Payment for the acquisition of land use right	`PaymentsToLandUseRights`	$12.12M	USD	2 Qtrs
Purchases of investments	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$27.65M	USD	2 Qtrs
Purchases of investments	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$1.20B	USD	2 Qtrs
Proceeds from sale or maturity of available-for-sale securities	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$161.90M	USD	2 Qtrs
Proceeds from sale or maturity of available-for-sale securities	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$869.01M	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$10.00M	USD	2 Qtrs
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$113.25M	USD	2 Qtrs
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-360.22M	USD	2 Qtrs
Proceeds from public offering, net of underwriter discount	`ProceedsFromIssuanceOfCommonStockNetOfUnderwriterDiscount`	$758.00M	USD	2 Qtrs
Payment of public offering cost	`PaymentsOfStockIssuanceCosts`	$414.00K	USD	2 Qtrs
Proceeds from long-term loan	`ProceedsFromLongTermLinesOfCredit`	$42.31M	USD	2 Qtrs
Proceeds from short-term loan	`ProceedsFromShortTermDebt`	$2.47M	USD	2 Qtrs
Repayment of short-term loan	`RepaymentsOfShortTermDebt`	$2.47M	USD	2 Qtrs
Capital contribution from noncontrolling interest	`ProceedsFromMinorityShareholders`	$14.53M	USD	2 Qtrs
Proceeds from shareholder loan	`ProceedsFromRelatedPartyDebt`	$132.76M	USD	2 Qtrs
Proceeds from option exercises	`ProceedsFromStockOptionsExercised`	$10.58M	USD	2 Qtrs
Proceeds from option exercises	`ProceedsFromStockOptionsExercised`	$316.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$810.48M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$147.60M	USD	2 Qtrs
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78M	USD	2 Qtrs
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$240.00K	USD	2 Qtrs
Net increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$230.41M	USD	2 Qtrs
Net increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$173.49M	USD	2 Qtrs
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$87.51M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$470.01M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$239.60M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$261.01M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$87.51M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$470.01M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$239.60M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$261.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$261.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$239.60M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$438.42M	USD	Point-in-time
Restricted Cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$31.59M	USD	Point-in-time
Income taxes paid	`IncomeTaxesPaidNet`	$746.00K	USD	2 Qtrs
Income taxes paid	`IncomeTaxesPaidNet`	$11.84M	USD	2 Qtrs
Interest expense paid	`InterestPaidNet`	$618.00K	USD	2 Qtrs
Interest expense paid	`InterestPaidNet`	$667.00K	USD	2 Qtrs
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$1.37M	USD	2 Qtrs
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$8.01M	USD	2 Qtrs
Changes in operating assets and liabilities adjusted through accumulated deficit	`CumulativeEffectOnRetainedEarningsNetOfTax1`	$2.29M	USD	2 Qtrs

Comprehensive Income 24 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-262.83M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-60.68M	USD	1 Quarter
Net loss	`ProfitLoss`	$-157.72M	USD	1 Quarter
Net loss	`ProfitLoss`	$-111.30M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$554.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$644.00K	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$2.03M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$2.31M	USD	2 Qtrs
Unrealized holding gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$719.00K	USD	1 Quarter
Unrealized holding gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$19.00K	USD	1 Quarter
Unrealized holding gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$7.00K	USD	2 Qtrs
Unrealized holding gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.05M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-110.65M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-259.48M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-60.11M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-154.96M	USD	1 Quarter
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-108.00K	USD	2 Qtrs
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-108.00K	USD	1 Quarter
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-1.33M	USD	2 Qtrs
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-870.00K	USD	1 Quarter
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-60.00M	USD	1 Quarter
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-258.15M	USD	2 Qtrs
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-110.54M	USD	2 Qtrs
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-154.09M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.